WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555273
CAS#: 1513879-19-0
Description: KDU691 is a plasmodium PI4K inhibitor (IC50 values of 0.18 μM and 0.061 μM against hypnozoite forms and liver schizontsm, respectively). KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites.
Hodoodo Cat#: H555273
Name: KDU691
CAS#: 1513879-19-0
Chemical Formula: C22H18ClN5O2
Exact Mass: 419.11
Molecular Weight: 419.869
Elemental Analysis: C, 62.93; H, 4.32; Cl, 8.44; N, 16.68; O, 7.62
Synonym: KDU691; KDU-691; KDU 691;
IUPAC/Chemical Name: N-(4-chlorophenyl)-N-methyl-3-(4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyrazine-6-carboxamide
InChi Key: TYMFFISSODJRDV-UHFFFAOYSA-N
InChi Code: InChI=1S/C22H18ClN5O2/c1-24-21(29)15-5-3-14(4-6-15)19-11-26-20-12-25-18(13-28(19)20)22(30)27(2)17-9-7-16(23)8-10-17/h3-13H,1-2H3,(H,24,29)
SMILES Code: ClC1=CC=C(N(C(C2=CN3C(C=N2)=NC=C3C4=CC=C(C(NC)=O)C=C4)=O)C)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 419.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Orjuela-Sanchez P, Villa ZH, Moreno M, Tong-Rios C, Meister S, LaMonte GM,
Campo B, Vinetz JM, Winzeler EA. Developing Plasmodium vivax Resources for Liver
Stage Study in the Peruvian Amazon Region. ACS Infect Dis. 2018 Apr
13;4(4):531-540. doi: 10.1021/acsinfecdis.7b00198. Epub 2018 Mar 15. PubMed PMID:
29542317.
2: Dembele L, Ang X, Chavchich M, Bonamy GMC, Selva JJ, Lim MY, Bodenreider C,
Yeung BKS, Nosten F, Russell BM, Edstein MD, Straimer J, Fidock DA, Diagana TT,
Bifani P. The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits
dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci
Rep. 2017 May 24;7(1):2325. doi: 10.1038/s41598-017-02440-6. PubMed PMID:
28539634; PubMed Central PMCID: PMC5443816.
3: Zeeman AM, Lakshminarayana SB, van der Werff N, Klooster EJ, Voorberg-van der
Wel A, Kondreddi RR, Bodenreider C, Simon O, Sauerwein R, Yeung BK, Diagana TT,
Kocken CH. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in
Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016 Apr
22;60(5):2858-63. doi: 10.1128/AAC.03080-15. Print 2016 May. PubMed PMID:
26926645; PubMed Central PMCID: PMC4862498.
